Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Apex BiotechnologyTPE:1733 +0.81%80 Debt-to-EBITDA is 0.60 as of Jun. 2026, which is 59% below its 10-year median of 1.45. GuruFocus rates TPE:1733 with a GF Score™ of 80/100 and a GF Value™ of NT$29.74 (Fairly Valued). The stock has 2 warning signs investors should review. Among 302 Biotechnology companies, Apex Biotechnology ranks better than 61.59% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Apex Biotechnology's Debt-to-EBITDA or its related term are showing as below:
TPE:1733'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.59 Med: 1.45 Max: 2.83
Current: 0.61
During the past 13 years, the highest Debt-to-EBITDA Ratio of Apex Biotechnology was 2.83. The lowest was 0.59. And the median was 1.45.
TPE:1733's Debt-to-EBITDA is ranked better than 61.59% of 302
companies
in the Biotechnology industry
Industry Median: 1.29
vs TPE:1733: 0.61
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Apex Biotechnology Debt-to-EBITDA Related Terms
Apex Biotechnology Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Apex Biotechnology's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:1733 vs VRTX, REGN, RVMD: Debt-to-EBITDA Comparison
For the Biotechnology subindustry, Apex Biotechnology's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Apex Biotechnology Debt-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Apex Biotechnology's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Apex Biotechnology's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
Apex Biotechnology (TPE:1733) has a Debt-to-EBITDA of 0.60 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Apex Biotechnology. This is 59% below median its historical median of 1.45. Over the past decade, Apex Biotechnology's Debt-to-EBITDA has ranged from 0.59 to 2.83. According to the industry distribution chart, Apex Biotechnology ranks #116 out of 302 companies in the Biotechnology industry, placing it in the top 38.4%.
Is Apex Biotechnology's Debt-to-EBITDA too high?
Apex Biotechnology's current Debt-to-EBITDA of 0.60 is 59% below median its 10-year median of 1.45. Over the past 10 years, this metric has ranged from a low of 0.59 to a high of 2.83. The Biotechnology industry median Debt-to-EBITDA is 1.29. Apex Biotechnology's value of 0.60 is 53.5% below this industry median. Based on the distribution chart, Apex Biotechnology ranks #116 out of 302 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Apex Biotechnology has a GF Score™ of 80/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Apex Biotechnology's Debt-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Apex Biotechnology ranks #116 out of 302 companies for Debt-to-EBITDA. This puts Apex Biotechnology in the upper half of its industry. The industry median Debt-to-EBITDA is 1.29. Apex Biotechnology's value of 0.60 is 53.5% below this benchmark. Historically, Apex Biotechnology's own Debt-to-EBITDA has ranged from 0.59 to 2.83 over the past decade. While the company's 10-year median is 1.45 vs. the industry median of 1.29, Apex Biotechnology has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Biotechnology company?
The median Debt-to-EBITDA among Biotechnology companies is 1.29, based on 302 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Apex Biotechnology's current Debt-to-EBITDA of 0.60 is 53.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Apex Biotechnology. For the Biotechnology industry, the median Debt-to-EBITDA is 1.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Apex Biotechnology's current Debt-to-EBITDA is 0.60, which is 59% below median its own 10-year median of 1.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Apex Biotechnology stock overvalued right now?
Based on GuruFocus' analysis, Apex Biotechnology (TPE:1733) is currently considered Fairly Valued. The stock's GF Value™ is NT$29.74, compared to a current price of NT$31.05 — trading 4.4% above its estimated fair value. The current Debt-to-EBITDA is 0.60, which is 59% below median its 10-year median of 1.45 and 53.5% below the Biotechnology industry median of 1.29. Apex Biotechnology's overall GF Score™ is 80/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Apex Biotechnology (TPE:1733), the current Debt-to-EBITDA is 0.60 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Apex Biotechnology (TPE:1733) Overvalued in 2026?
Based on GuruFocus' analysis, Apex Biotechnology stock appears to be overvalued.
The current stock price of NT$31.05 is trading 4.4% above its estimated GF Value™ of NT$29.74.
GuruFocus considers Apex Biotechnology to be Fairly Valued.
Key valuation signals for TPE:1733:
Debt-to-EBITDA: 0.60 (59% below median its 10-year median of 1.45)
GF Value™: NT$29.74 vs. price of NT$31.05 (4.4% above fair value)
Industry Position: 53.5% below the Biotechnology median (#116 of 302)
No single metric tells the full story. See the TPE:1733 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Apex Biotechnology Corp is engaged in the research, development, production, manufacturing, and sale of biochemical testing instruments and proprietary test strips, as well as the import and export of products and components related to its core business. Its product offerings include diabetes testing kits, blood uric acid monitoring systems, blood lactate monitoring systems, blood haemoglobin monitoring systems, etc. The company generates maximum revenue from the sale of test strips, and the rest from testing meters, electrodes, and other products. Geographically, it derives maximum revenue from the USA, and the rest from Italy, Austria, Taiwan, China, and other markets.
80GF Score
Get the complete analysis for TPE:1733
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1733 has been successfully added to your 
